Valneva Prepares for Shareholder Meeting and Announces Leadership Change

Valneva ( (VALN) ) has provided an update.

On June 4, 2025, Valneva SE announced the availability of documentation for its Combined General Meeting scheduled for June 25, 2025, in Lyon, France. The company also announced the departure of Franck Grimaud, Chief Business Officer and co-founder, effective the same date. Grimaud has been with Valneva and its predecessor Vivalis for 26 years, contributing significantly to the company’s development and strategy, particularly in its commercial vaccine business.

The most recent analyst rating on (VALN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Spark’s Take on VALN Stock

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

Valneva’s overall stock score is primarily impacted by its weak financial performance and valuation. Despite technical indicators being neutral, strong revenue growth and regulatory achievements provide some positive outlook. However, significant operational and financial challenges remain.

To see Spark’s full report on VALN stock, click here.

More about Valneva

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is working on vaccine candidates for Lyme disease, Shigella, and Zika virus.

Average Trading Volume: 77,411

Technical Sentiment Signal: Sell

Current Market Cap: $544.5M

Learn more about VALN stock on TipRanks’ Stock Analysis page.